Emory University: Glioblastoma trials

The registry lists 11 Glioblastoma studies with Emory University as lead sponsor. 1 are open to participants now and 3 have results posted.

Early Phase 1 4Phase 1 2Phase 2 5No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated GlioblastomaRecruitingNCT04590664Phase 1/2
• Spectroscopic MRI-Guided Radiation Therapy Planning in GlioblastomaCompletedNCT03137888Phase 2Results posted
• Phase 0 Analysis of Ixazomib (MLN9708) in Patients With GlioblastomaCompletedNCT02630030Early Phase 1Results posted
• A Study of Subcutaneous Bevacizumab in Relapsed / Progressive GlioblastomaCompletedNCT02157103Phase 2Results posted
• Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With GlioblastomaActive, not recruitingNCT05798507Early Phase 1
• Investigational Imaging Technique During Brain SurgerySuspendedNCT05513859Not applicable
• Natural Progesterone for the Treatment of Recurrent GlioblastomaTerminatedNCT05091866Early Phase 1
• Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or GliosarcomaWithdrawnNCT05017610Early Phase 1
• MRSI to Predict Response to RT/TMZ ± Belinostat in GBMActive, not recruitingNCT02137759Phase 2
• Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma MultiformeCompletedNCT01435395Phase 1
• Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain NeoplasmsCompletedNCT00004688Phase 2